Minireviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2020; 26(17): 2040-2048
Published online May 7, 2020. doi: 10.3748/wjg.v26.i17.2040
Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations
Adriano Carneiro da Costa, Mikael Sodergren, Kumar Jayant, Fernando Santa Cruz, Duncan Spalding, Madhava Pai, Nagy Habib
Adriano Carneiro da Costa, Mikael Sodergren, Kumar Jayant, Fernando Santa Cruz, Duncan Spalding, Madhava Pai, Nagy Habib, Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, United Kingdom
Author contributions: da Costa AC performed the majority of the writing; Sodergren M, Jayant K and Santa Cruz F performed data accusation and writing; Spalding D provided the input in writing the paper; Pai M and Habib N designed the outline and coordinated the writing of the paper.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Nagy Habib, FRCS (Gen Surg), Chairman, Professor, Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, 1st Floor B Block, Du Cane Road, London W12 0NN, United Kingdom. nagy.habib@imperial.ac.uk
Received: February 9, 2020
Peer-review started: February 9, 2020
First decision: February 27, 2020
Revised: March 25, 2020
Accepted: April 15, 2020
Article in press: April 15, 2020
Published online: May 7, 2020
Core Tip

Core tip: Radiofrequency ablation (RFA) is a well-established surgical approach to treat hepatocellular carcinoma (HCC). However, it has the inconvenience of being related to tumor recurrence. The combination of RFA and immunotherapy has emerged as a promising approach to activate and potentialize local and systemic immune responses. It has potential to reinstate anti-tumor immunity in HCC through increase in antitumor T cell response. The approach seems quite pragmatic in limiting the recurrence and improving survival rates compared to RFA alone for HCC patients. Currently, there are only eight articles in the literature that studied the combination of RFA and immunotherapy.